SHR-RAS001

SHR-RAS001 is a structurally novel, highly potent cyclophilin A (CypA)-dependent tri-complex RAS multi (ON) inhibitor developed for the treatment of RAS-mutant malignancies. It functions by binding to the intracellular chaperone protein CypA (Peptidyl-prolyl cis-trans isomerase A) and subsequently recruiting either wild-type or mutant RAS proteins, including frequent variants such as G12D, G12V, G13D, and Q61H. The resulting ternary complex sterically disrupts the interaction between active RAS and its downstream effector RAF, effectively blocking oncogenic signaling. Developed by Jiangsu Hengrui Pharmaceuticals, SHR-RAS001 has demonstrated potent cell-killing activity across various RAS-mutant cell lines and robust antitumor efficacy in xenograft models of pancreatic, colorectal, and non-small cell lung cancers. It is currently being evaluated in an open-label, multicenter Phase I clinical study for patients with advanced solid tumors.